home / stock / imgn / imgn news


IMGN News and Press, ImmunoGen Inc. From 06/23/23

Stock Information

Company Name: ImmunoGen Inc.
Stock Symbol: IMGN
Market: NASDAQ
Website: immunogen.com

Menu

IMGN IMGN Quote IMGN Short IMGN News IMGN Articles IMGN Message Board
Get IMGN Alerts

News, Short Squeeze, Breakout and More Instantly...

IMGN - Top 10 Mid-Cap performers of 2023, including C3.ai and Riot Platforms

2023-06-23 11:12:16 ET As Wall Street approaches the midpoint of 2023, many mid-cap stocks have provided investors with sizable returns. Of the roughly 1,000 mid-cap stocks available for investors, 101 of them have returned 50% or more since the end of 2022. This includes several ralli...

IMGN - IMGN, VSTM and ESPR are among pre market gainers

2023-06-15 08:21:52 ET Leju Holdings  ( LEJU ) +40% . CBAK Energy Technology ( CBAT ) +26% Received Order From Viessmann Group for EUR116.5 Million of Lithium-Ion Batteries for 2024. BitNile Metaverse ( BNMV ) +24% . Applied UV ( AUVI ) +20% ...

IMGN - ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

Interim Analysis from Phase 2 Trial Demonstrates Compelling Anti-Tumor Activity in Patients with Frontline and Relapsed/Refractory BPDCN; No New Safety Signals Identified Enrollment Continues in Frontline CADENZA Cohort; Top-Line Pivotal Data Expected in 2024 ImmunoGen Inc. ...

IMGN - These 14%+ Sucker Yields Could Cut Dividend, But There's A Better Way

2023-06-07 07:00:00 ET Summary High-yield dividend stocks are appealing, but they carry high amounts of risk. I demonstrate multiple examples. We present our new strategy to achieve high yields and 76 trades to snipe at market open. Written by Sam Kovacs Intr...

IMGN - ImmunoGen jumps 17% after ASCO readout on Elahere cancer drug

2023-06-05 07:00:59 ET ImmunoGen Inc. ( NASDAQ: IMGN ) added ~17% pre-market Monday after the company shared data from a Phase 3 confirmatory trial for its antibody-drug conjugate Elahere at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. Announcing dat...

IMGN - ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FR?-Positive Platinum-Resistant Ovarian Cancer

Results from MIRASOL Also Show ELAHERE is the First Treatment to Demonstrate an Overall Survival Benefit in a Phase 3 Trial in Platinum-Resistant Ovarian Cancer Compared to Chemotherapy Clinically Meaningful Improvements in Progression Free Survival and Overall Survival Observed with ELAH...

IMGN - Wall Street Breakfast: The Week Ahead

2023-06-04 07:30:00 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: The Week Ahead

IMGN - Promising New Cancer Treatment Data to Be Presented at 2023 ASCO Annual Meeting

VANCOUVER - USA News Group - The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023 , with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there’s ple...

IMGN - Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

2023-05-26 10:45:42 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – May 26, 2023 – USA News Group –  The world’s biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 20...

IMGN - ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Healthca...

Previous 10 Next 10